{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:00:04Z","timestamp":1788670804831,"version":"build-2803163510"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2018D-2498"],"award-info":[{"award-number":["RIA2018D-2498"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>During TB-case finding, we assessed the feasibility of implementing the advanced HIV disease (AHD) care package, including VISITECT CD4 Advanced Disease (VISITECT), a semiquantitative test to identify a CD4\u2264200cells\/\u03bcl. Adult participants with tuberculosis symptoms, recruited near-facility in Lesotho and South-Africa between 2021\u20132022, were offered HIV testing (capillary blood), Xpert MTB\/RIF and Ultra, and MGIT culture (sputum). People living with HIV (PLHIV) were offered VISITECT (venous blood) and Alere tuberculosis-lipoarabinomannan (AlereLAM, urine) testing. AHD was defined as a CD4\u2264200cells\/\u03bcl on VISITECT or a positive tuberculosis test. A CD4\u2264200cells\/\u03bcl on VISITECT triggered Immy cryptococcal antigen (Immy CrAg, plasma) testing. Participants were referred with test results. To evaluate feasibility, we assessed i) acceptability and ii) intervention delivery of point-of-care diagnostics among study staff using questionnaires and group discussions, iii) process compliance, and iv) early effectiveness (12-week survival and treatment status) in PLHIV. Predictors for 12-week survival were assessed with logistic regression. Thematic content analysis and triangulation were performed. Among PLHIV (N = 676, 48.6% of 1392 participants), 7.8% were newly diagnosed, 81.8% on ART, and 10.4% knew their HIV status but were not on ART. Among 676 PLHIV, 41.7% had AHD, 29.9% a CD4\u2264200cells\/\u03bcl and 20.6% a tuberculosis diagnosis. Among 200 PLHIV tested with Immy CrAg, 4.0% were positive. The procedures were acceptable for study staff, despite intervention delivery challenges related to supply and the long procedural duration (median: 73 minutes). At 12 weeks, among 276 PLHIV with AHD and 328 without, 3.3% and 0.9% had died, 84.8% and 92.1% were alive and 12.0% and 7.0% had an unknown status, respectively. Neither AHD nor tuberculosis status were associated with survival. Implementing AHD care package diagnostics was feasible during tuberculosis-case finding. AHD was prevalent, and not associated with survival, which is likely explained by the low specificity of VISITECT. Challenges with CD4 testing and preventive treatment uptake require addressing.<\/jats:p>","DOI":"10.1371\/journal.pone.0296197","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T18:29:03Z","timestamp":1703269743000},"page":"e0296197","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Implementation of the advanced HIV disease care package with point-of-care CD4 testing during tuberculosis case finding: A mixed-methods evaluation"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5518-9600","authenticated-orcid":true,"given":"Tinne","family":"Gils","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashaete","family":"Kamele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thandanani","family":"Madonsela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Bosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thulani","family":"Ngubane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Reither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moniek","family":"Bresser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Vlieghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1205-1484","authenticated-orcid":true,"given":"Tom","family":"Decroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ayakaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutgarde","family":"Lynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Van Heerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"issue":"suppl_2","key":"pone.0296197.ref001","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1093\/cid\/cix1140","article-title":"The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa","volume":"66","author":"M Osler","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"suppl_2","key":"pone.0296197.ref002","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1093\/cid\/cix1138","article-title":"The persistent challenge of advanced HIV disease and AIDS in the era of antiretroviral therapy","volume":"66","author":"A Calmy","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pone.0296197.ref003","volume-title":"HIV treatment: guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy: policy brief","author":"World Health Organization","year":"2017"},{"issue":"suppl_2","key":"pone.0296197.ref004","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1093\/cid\/cix1139","article-title":"Managing Advanced HIV Disease in a Public Health Approach","volume":"66","author":"N Ford","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"9983","key":"pone.0296197.ref005","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(15)60164-7","article-title":"Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial","volume":"385","author":"S Mfinanga","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"pone.0296197.ref006","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1615822","article-title":"Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa","volume":"377","author":"J Hakim","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0296197.ref007","volume-title":"UNAIDS Global AIDS update 2022","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)"},{"issue":"7","key":"pone.0296197.ref008","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/S2352-3018(20)30101-6","article-title":"Framework for the implementation of advanced HIV disease diagnostics in sub-Saharan Africa: programmatic perspectives","volume":"7","author":"Z Ndlovu","year":"2020","journal-title":"Lancet HIV"},{"key":"pone.0296197.ref009","volume-title":"Point-of-care CD4 tests to support the identification of individuals with advanced HIV disease, 03 April 2020","author":"World Health Organization","year":"2020"},{"issue":"4","key":"pone.0296197.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230453","article-title":"Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening","volume":"15","author":"Z Ndlovu","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"pone.0296197.ref011","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/QAI.0000000000003092","article-title":"Laboratory evaluation of the VISITECT advanced disease semiquantitative point-of-care CD4 test","volume":"91","author":"K Lechiile","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"pone.0296197.ref012","doi-asserted-by":"crossref","first-page":"e057291","DOI":"10.1136\/bmjopen-2021-057291","article-title":"Feasibility of implementing the advanced HIV disease care package as part of community-based HIV\/TB activities: a mixed-methods study protocol","volume":"12","author":"T Gils","year":"2022","journal-title":"BMJ Open"},{"key":"pone.0296197.ref013","volume-title":"UNAIDS country factsheets","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2021"},{"key":"pone.0296197.ref014","volume-title":"UNAIDS Data","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2020"},{"key":"pone.0296197.ref015","volume-title":"National Consolidated Guidelines for the management of HIV in adults, pregnancy, adolescents, children and infants and prevention of mother-to-child transmission","author":"Republic of South Africa National Department of Health","year":"2020"},{"key":"pone.0296197.ref016","volume-title":"Ministry of Health Government of LesothoApproach to the management of advanced HIV disease (AHD)","year":"2020"},{"issue":"7262","key":"pone.0296197.ref017","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/bmj.321.7262.694","article-title":"Framework for design and evaluation of complex interventions to improve health","volume":"321","author":"M Campbell","year":"2000","journal-title":"BMJ"},{"issue":"5","key":"pone.0296197.ref018","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ijnurstu.2012.09.010","article-title":"Developing and evaluating complex interventions: the new Medical Research Council guidance","volume":"50","author":"P Craig","year":"2008","journal-title":"Int J Nurs Stud"},{"issue":"11","key":"pone.0296197.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277812","article-title":"Recent HIV infections among newly diagnosed individuals living with HIV in rural Lesotho: Secondary data from the VIBRA cluster-randomized trial","volume":"17","author":"T Mohloanyane","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pone.0296197.ref020","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2019.1679472","article-title":"Distribution of advanced HIV disease from three high HIV prevalence settings in Sub-Saharan Africa: a secondary analysis data from three population-based cross-sectional surveys in Eshowe (South Africa), Ndhiwa (Kenya) and Chiradzulu (Malawi)","volume":"12","author":"ML Chihana","year":"2019","journal-title":"Glob Health Action"},{"issue":"2","key":"pone.0296197.ref021","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01277-18","article-title":"Field performance and diagnostic accuracy of a low-cost instrument-free point-of-care CD4 test (Visitect CD4) performed by different health worker cadres among pregnant women","volume":"57","author":"S Luchters","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"1","key":"pone.0296197.ref022","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4102\/ajlm.v7i1.757","article-title":"District and sub-district analysis of cryptococcal antigenaemia prevalence and specimen positivity in KwaZulu-Natal, South Africa","volume":"7","author":"N Cassim","year":"2018","journal-title":"Afr J Lab Med"},{"issue":"1","key":"pone.0296197.ref023","article-title":"The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells\/\u03bcL: evidence based on a meta-analysis","volume":"20","author":"Y Li","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0296197.ref024","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/S2214-109X(22)00463-6","article-title":"Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study","volume":"11","author":"H Huerga","year":"2023","journal-title":"Lancet Glob Health"},{"key":"pone.0296197.ref025","volume-title":"Making it count: Acces to CD4 point-of-care testing under threat Geneva","author":"M\u00e9decins Sans Fronti\u00e8res","year":"2023"},{"issue":"1","key":"pone.0296197.ref026","doi-asserted-by":"crossref","first-page":"1672366","DOI":"10.1080\/16549716.2019.1672366","article-title":"Feasibility of using Determine TB-LAM to diagnose tuberculosis in HIV-positive patients in programmatic conditions: a multisite study","volume":"12","author":"SC Mathabire Rucker","year":"2019","journal-title":"Glob Health Action"},{"issue":"2","key":"pone.0296197.ref027","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/00365548.2013.853133","article-title":"Reasons for false-positive lipoarabinomannan ELISA results in a Tanzanian population","volume":"46","author":"I Kroidl","year":"2014","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"pone.0296197.ref028","doi-asserted-by":"crossref","first-page":"e00208","DOI":"10.1128\/spectrum.00208-22","article-title":"Diagnostic accuracy of urine lipoarabinomannan testing in early morning urine versus spot urine for diagnosis of tuberculosis among people with HIV","volume":"10","author":"S Bjerrum","year":"2022","journal-title":"Microbiol Spectr"},{"key":"pone.0296197.ref029","doi-asserted-by":"crossref","first-page":"100316","DOI":"10.1016\/j.jctube.2022.100316","article-title":"Feasibility and acceptability of using the novel urine-based FujiLAM test to detect tuberculosis: A multi-country mixed-methods study","volume":"27","author":"CMS R\u00fccker","year":"2022","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"9","key":"pone.0296197.ref030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183656","article-title":"Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho","volume":"12","author":"F Rick","year":"2017","journal-title":"PLoS One"},{"issue":"31","key":"pone.0296197.ref031","doi-asserted-by":"crossref","first-page":"e11722","DOI":"10.1097\/MD.0000000000011722","article-title":"A qualitative evaluation of an implementation study for cryptococcal antigen screening and treatment in Uganda","volume":"97","author":"SM Lofgren","year":"2018","journal-title":"Medicine"},{"issue":"8","key":"pone.0296197.ref032","doi-asserted-by":"crossref","first-page":"e25775","DOI":"10.1002\/jia2.25775","article-title":"Improved detection and management of advanced HIV disease through a community adult TB-contact tracing intervention with same-day provision of the WHO-recommended package of care including ART initiation in a rural district of Mozambique","volume":"24","author":"S Izco","year":"2021","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"pone.0296197.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251612","article-title":"Mixed methods systematic review and metasummary about barriers and facilitators for the implementation of cotrimoxazole and isoniazid\u2014Preventive therapies for people living with HIV","volume":"17","author":"P M\u00fcller","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pone.0296197.ref034","first-page":"1266","article-title":"Establishing targets for advanced HIV disease: A call to action","volume":"22","author":"DB Meya","year":"2021","journal-title":"South Afr J HIV Med"},{"issue":"6","key":"pone.0296197.ref035","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2352-3018(23)00078-4","article-title":"Management of advanced HIV disease in Africa","volume":"10","author":"S Izco","year":"2023","journal-title":"Lancet HIV"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0296197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T18:29:29Z","timestamp":1703269769000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0296197"}},"subtitle":[],"editor":[{"given":"Lynn S.","family":"Zijenah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0296197","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]}}}